Skip to main content
SpringerLink
Log in

Deferasirox AUC efficacy cutoff and role of pharmacogenetics

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, Grant FD, Paley C, Shannon M, Neufeld EJ (2009) Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 114(19):4009–4013. doi:10.1182/blood-2009-05-222729

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, Boernsen KO, Waldmeier F (2008) Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 36(12):2523–2538. doi:10.1124/dmd.108.022962

    Article  CAS  PubMed  Google Scholar 

  3. Cusato J, Allegra S, Massano D, De Francia S, Piga A, D’Avolio A (2015) Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J 15(3):263–271. doi:10.1038/tpj.2014.65

    Article  CAS  PubMed  Google Scholar 

  4. De Francia S, Massano D, Piccione FM, Pirro E, Racca S, Di Carlo F, Piga A (2012) A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. J Chromatogr B Analyt Technol Biomed Life Sci 893-894: 127-133 DOI 10.1016/j.jchromb.2012.02.047

  5. Delord M, Rousselot P, Cayuela JM, Sigaux F, Guilhot J, Preudhomme C, Guilhot F, Loiseau P, Raffoux E, Geromin D, Genin E, Calvo F, Bruzzoni-Giovanelli H (2013) High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget 4(10):1582–1591. doi:10.18632/oncotarget.1050

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank CoQua Lab (www.coqualab.it) for its methodological support and assistance in the preparation and execution of the study and analysis.

Author information

Authors and Affiliations

  1. Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, Unit of Infectious Diseases, Amedeo di Savoia Hospital University of TorinoCorso Svizzera 16410149 TurinItaly, University of Turin, 10149, Turin, Italy

    S. Allegra, J. Cusato & A. D’Avolio

  2. Department of Biological and Clinical Sciences, S. Luigi Gonzaga Hospital, University of Turin, 10043, Orbassano, TO, Italy

    S. De Francia

  3. Department of Pediatrics, Centre for Microcitemie, S. Luigi Gonzaga Hospital, University of Turin, 10043, Orbassano, TO, Italy

    D. Massano & A. Piga

Authors
  1. S. Allegra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Cusato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. De Francia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Massano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Piga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. D’Avolio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. D’Avolio.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

*UNI EN ISO 9001:2008 Certified Laboratory; Certificate No. IT-64386; ** Certification for: “DESIGN, DEVELOPMENT AND APPLICATION OF DETERMINATION METHODS FOR ANTI-INFECTIVE DRUGS. PHARMACOGENETIC ANALYSES.”

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Allegra, S., Cusato, J., De Francia, S. et al. Deferasirox AUC efficacy cutoff and role of pharmacogenetics. Eur J Clin Pharmacol 72, 1155–1157 (2016). https://doi.org/10.1007/s00228-016-2070-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-016-2070-9

Keywords

Search

Navigation